<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xml:lang="en" article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink">
<?release-delay 0|0?>
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">MCO</journal-id>
<journal-title-group>
<journal-title>Molecular and Clinical Oncology</journal-title>
</journal-title-group>
<issn pub-type="ppub">2049-9450</issn>
<issn pub-type="epub">2049-9469</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">MCO-0-0-02168</article-id>
<article-id pub-id-type="doi">10.3892/mco.2020.2168</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Relationship between PDGFR expression and the response to pazopanib in intimal sarcoma of the pulmonary artery: A case report</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Sai</surname><given-names>Satoshi</given-names></name>
<xref rid="af1-mco-0-0-02168" ref-type="aff">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Imamura</surname><given-names>Yoshinori</given-names></name>
<xref rid="af1-mco-0-0-02168" ref-type="aff">1</xref>
<xref rid="c1-mco-0-0-02168" ref-type="corresp"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Kiyota</surname><given-names>Naomi</given-names></name>
<xref rid="af1-mco-0-0-02168" ref-type="aff">1</xref>
<xref rid="af2-mco-0-0-02168" ref-type="aff">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Jimbo</surname><given-names>Naoe</given-names></name>
<xref rid="af3-mco-0-0-02168" ref-type="aff">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Toyoda</surname><given-names>Masanori</given-names></name>
<xref rid="af1-mco-0-0-02168" ref-type="aff">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Funakoshi</surname><given-names>Yohei</given-names></name>
<xref rid="af1-mco-0-0-02168" ref-type="aff">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Chayahara</surname><given-names>Naoko</given-names></name>
<xref rid="af1-mco-0-0-02168" ref-type="aff">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Hyogo</surname><given-names>Yasuko</given-names></name>
<xref rid="af1-mco-0-0-02168" ref-type="aff">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Takenaka</surname><given-names>Kei</given-names></name>
<xref rid="af1-mco-0-0-02168" ref-type="aff">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Suto</surname><given-names>Hirotaka</given-names></name>
<xref rid="af1-mco-0-0-02168" ref-type="aff">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Minami</surname><given-names>Hironobu</given-names></name>
<xref rid="af1-mco-0-0-02168" ref-type="aff">1</xref>
<xref rid="af2-mco-0-0-02168" ref-type="aff">2</xref>
</contrib>
</contrib-group>
<aff id="af1-mco-0-0-02168"><label>1</label>Department of Medical Oncology/Hematology, Kobe University Hospital and Graduate School of Medicine, Kobe City, Hyogo 650-0017, Japan</aff>
<aff id="af2-mco-0-0-02168"><label>2</label>Cancer Center, Kobe University Hospital, Kobe City, Hyogo 650-0017, Japan</aff>
<aff id="af3-mco-0-0-02168"><label>3</label>Department of Diagnostic Pathology, Kobe University Hospital and Graduate School of Medicine, Kobe City, Hyogo 650-0017, Japan</aff>
<author-notes>
<corresp id="c1-mco-0-0-02168"><italic>Correspondence to:</italic> Dr Yoshinori Imamura, Department of Medical Oncology/Hematology, Kobe University Hospital and Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe City, Hyogo 650-0017, Japan <email>yimamura@med.kobe-u.ac.jp</email></corresp>
</author-notes>
<pub-date pub-type="ppub">
<month>01</month>
<year>2021</year></pub-date>
<pub-date pub-type="epub">
<day>09</day>
<month>11</month>
<year>2020</year></pub-date>
<volume>14</volume>
<issue>1</issue>
<elocation-id>6</elocation-id>
<history>
<date date-type="received">
<day>30</day>
<month>05</month>
<year>2020</year>
</date>
<date date-type="accepted">
<day>15</day>
<month>09</month>
<year>2020</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright: &#x00A9; Sai et al.</copyright-statement>
<copyright-year>2020</copyright-year>
<license license-type="open-access">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivs License</ext-link>, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.</license-p></license>
</permissions>
<abstract>
<p>Intimal sarcoma of the pulmonary artery (PAIS) is a rare disease with a poor prognosis. Pazopanib, which has been indicated in metastatic non-adipocytic soft-tissue sarcomas and is expected to be active in PAIS, is a multi-kinase inhibitor that targets the tyrosine kinase activity of vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and stem cell factor receptor. The present study reports findings related to two cases of PAIS with PDGF and VEGF expression following treatment with pazopanib. A case with a moderate to strong expression of PDGFR-&#x03B1; and -&#x03B2; presented a long-term stable disease when treated with pazopanib (progression-free survival, 5.8 months). In a second case with a weak expression of PDGFR-&#x03B1; and -&#x03B2;, the disease progressed rapidly on pazopanib (progression-free survival, 1.1 months). VEGFR-2 was not expressed in the tumors of both cases. The level of PDGFR expression in the tumor tissue may therefore be predictive of pazopanib efficacy.</p>
</abstract>
<kwd-group>
<kwd>case reports</kwd>
<kwd>intimal sarcoma</kwd>
<kwd>pazopanib</kwd>
<kwd>platelet-derived growth factor receptor</kwd>
<kwd>pulmonary artery</kwd>
<kwd>vascular endothelial growth factor receptor</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Intimal sarcoma of pulmonary artery (PAIS) is a rare disease which has a poor prognosis (<xref rid="b1-mco-0-0-02168" ref-type="bibr">1</xref>). PAIS is often diagnosed as advanced disease and has a high rate of postoperative recurrence. Although therapeutic options for PAIS are limited, several recent studies have reported that pazopanib, a multi-kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR)-1, -2, -3, platelet-derived growth factor (PDGF) receptor (PDGFR)-&#x03B1;, -&#x03B2; and stem cell factor receptor (c-Kit), shows activity in treatment for advanced vascular sarcomas, including PAIS (<xref rid="b2-mco-0-0-02168 b3-mco-0-0-02168 b4-mco-0-0-02168 b5-mco-0-0-02168" ref-type="bibr">2-5</xref>). However, these previous reports did not investigate the relationship between the levels of PDGFR and VEGFR in tumor tissues and the response to pazopanib. Our present report provides new information in this regard, as we studied this relationship in two cases of PAIS.</p>
</sec>
<sec sec-type="Case|report">
<title>Case report</title>
<sec>
<title/>
<sec>
<title>Case 1</title>
<p>A 33-year-old man visited a local hospital with a chronic cough. A CT scan showed an intravascular lesion of the left pulmonary artery and multiple masses in the left lung. He underwent pneumonectomy of the left lung for tumor embolism and angioplasty of the left pulmonary artery. In addition to the clinical course, immunohistochemical analysis showed spinal tumor cells were positive for murine double minute 2 (MDM2) and CD34, which led to the final diagnosis of PAIS. Because the margin of the left pulmonary artery base was positive for tumor cells, adjuvant irradiation (60 Gy/30 fr) and adjuvant chemotherapy with doxorubicin and ifosfamide (60/7,500 mg/m<sup>2</sup>/every 3 weeks, 1 cycle, AI therapy) were performed. However, recurrence was observed 2 months later. Pazopanib treatment was initiated and this stabilized the disease for 5.8 months, which is superior to the 2 months achieved with AI therapy. Subsequently, eribulin was administered, but a CT scan on day 14 of the 1st cycle showed rapid tumor growth, which was considered as flare-up upon the discontinuation of pazopanib. The patient died 2 months after the discontinuation of pazopanib, a total of 18 months after the diagnosis (<xref rid="tI-mco-0-0-02168" ref-type="table">Table I</xref>).</p>
<p>Immunohistochemistry revealed that tumor cells were moderately and strongly positive for PDGFR-&#x03B1; (Cell Signaling Technology, Inc.; cat. no. 3174; <xref rid="f1-mco-0-0-02168" ref-type="fig">Fig. 1A</xref>) and PFGFR-&#x03B2; (Abcam; cat. no. ab32570; <xref rid="f1-mco-0-0-02168" ref-type="fig">Fig. 1B</xref>), respectively, but negative for VEGFR-2 (Cell Signaling Technology, Inc.; cat. no. 2479; <xref rid="f1-mco-0-0-02168" ref-type="fig">Fig. 1C</xref>).</p>
</sec>
<sec>
<title>Case 2</title>
<p>A 44-year-old woman visited a local hospital with dyspnea on exertion, and a CT scan revealed an intravascular lesion of the left pulmonary artery and a mass in the right lung. She underwent right upper lobectomy and angioplasty of the left pulmonary artery. During postoperative recovery and preparation of therapy for the positive tumor cells at the resection margins, lung metastases developed 3 months after the surgery. Subsequently, palliative chemotherapy with doxorubicin (60 mg/m<sup>2</sup>/every 3 weeks, 6 cycles) followed by eribulin (1.4 mg/m<sup>2</sup>/every 3 weeks, 2 cycles) were administered sequentially, but neither treatments induced a response. Nine months after the diagnosis, pazopanib was initiated as a 3rd-line palliative pharmacotherapy. However, CT scans one month after the start of pazopanib revealed an increased tumor size. The patient died 14.3 months after the original diagnosis (<xref rid="tI-mco-0-0-02168" ref-type="table">Table I</xref>).</p>
<p>Immunohistochemistry revealed that the tumor cells were weakly positive for PDGFR-&#x03B1; (<xref rid="f1-mco-0-0-02168" ref-type="fig">Fig. 1A</xref>) and PDGFR-&#x03B2; (<xref rid="f1-mco-0-0-02168" ref-type="fig">Fig. 1B</xref>), and negative for VEGFR-2 (<xref rid="f1-mco-0-0-02168" ref-type="fig">Fig. 1C</xref>). Immunostaining was performed according to the following protocol. Paraffin sections of tumor tissues of pulmonary artery were subjected to immunohistochemical staining for the PDGFR-&#x03B1;,-&#x03B2;, VEGFR-2. At first, blocked specimen in blocking buffer for 1 h at room temperature. Blocking solution was removed and diluted primary antibodies were added (PDGFR-&#x03B1;: Cell Signaling Technology cat. no. 3174; PDGFR-&#x03B2;: Abcam cat. no. ab32570; VEGFR-2: Cell Signaling Technology cat. no. 3174) and incubated overnight at 4&#x02DA;C. Antibody solution was removed and the incubated specimen was mixed with fluorochrome-conjugated secondary antibody for 1-10 min at room temperature.</p>
</sec>
</sec>
</sec>
<sec sec-type="Discussion">
<title>Discussion</title>
<p>Through two cases of PAIS, the relationship between the expression of PDGFR or VEGFR and the response to pazopanib was investigated (<xref rid="tI-mco-0-0-02168" ref-type="table">Table I</xref>). In case 1, the tumor cells were strongly positive for PDGFR-&#x03B2; (<xref rid="f1-mco-0-0-02168" ref-type="fig">Fig. 1B</xref>) and moderately positive for PDGFR-&#x03B1; (<xref rid="f1-mco-0-0-02168" ref-type="fig">Fig. 1A</xref>). Time to progression before pazopanib was two months, but pazopanib treatment stabilized the tumor for 5.8 months. In the second case, the tumor cells were weakly positive for PDGFR-&#x03B1; (<xref rid="f1-mco-0-0-02168" ref-type="fig">Fig. 1A</xref>) and PDGFR-&#x03B2; (<xref rid="f1-mco-0-0-02168" ref-type="fig">Fig. 1B</xref>), which may explain the reduced response to treatment. Time to progression on pazopanib treatment was 1.1 months, while it took 3 months to progress after the surgery. Both cases were negative for expression of VEGFR-2 (<xref rid="f1-mco-0-0-02168" ref-type="fig">Fig. 1C</xref>). Focusing on these two cases, high levels of PDGFR in tumor tissues might have contributed to an improved response to pazopanib treatment.</p>
<p>Compared to placebo, pazopanib significantly improved PFS (median PFS, 4.6 months vs. 1.6 months) in patients with metastatic non-adipocytic soft-tissue sarcoma (<xref rid="b6-mco-0-0-02168" ref-type="bibr">6</xref>). According to a European Organization for Research and Treatment of Cancer (EORTC) retrospective analysis of pazopanib in patients with advanced vascular sarcoma, the median PFS and OS were 3.0 and 9.9 months, respectively. In this analysis, among the 40 patients with vascular sarcoma, 2 (3.8&#x0025;) had intimal sarcomas and both of these patients demonstrated a partial response (<xref rid="b2-mco-0-0-02168" ref-type="bibr">2</xref>). Unfortunately, the number of PAIS cases in this previous report was too low to investigate the relationship between PDGFR and VEGFR expression in tumor tissue and the response to pazopanib. To the best of our knowledge, this is the first study to demonstrate the relationships between PDGFR and VEGFR expression and the response to pazopanib.</p>
<p>Although pazopanib is a multi-kinase inhibitor (<xref rid="b1-mco-0-0-02168" ref-type="bibr">1</xref>), our results suggest that the activity against PDGF may account for its activity in PAIS. This is consistent with the role of PDGFs in other malignancies. PDGFs bind to PDGFR-&#x03B1; and -&#x03B2;, and trigger cell proliferation, migration and differentiation. In humans, abnormal PDGF/PDGFR signaling has been associated with numerous malignant tumors, including activating mutations of PDGFR-&#x03B1; in gastrointestinal stromal tumors and the overexpression of PDGFR-&#x03B2; in dermatofibrosarcoma protuberans (<xref rid="b7-mco-0-0-02168" ref-type="bibr">7</xref>,<xref rid="b8-mco-0-0-02168" ref-type="bibr">8</xref>). In addition to hematological tumors, PDGFR-&#x03B2; alterations are also involved in myofibromas, suggesting an oncogenic role in mesenchymal tumors (<xref rid="b9-mco-0-0-02168" ref-type="bibr">9</xref>). Amplifications of PDGFR-&#x03B1;, PDGFR-&#x03B2;, c-Kit, MDM2 and epidermal growth factor receptor (EGFR) have been seen in intimal sarcoma (<xref rid="b7-mco-0-0-02168" ref-type="bibr">7</xref>,<xref rid="b9-mco-0-0-02168 b10-mco-0-0-02168 b11-mco-0-0-02168 b12-mco-0-0-02168" ref-type="bibr">9-12</xref>). Alterations in the PDGF/PDGFR signaling pathway, particularly PDGFR-&#x03B1; and PDGFR-&#x03B2;, may play an important role in the pathogenesis of intimal sarcoma (<xref rid="b9-mco-0-0-02168" ref-type="bibr">9</xref>,<xref rid="b10-mco-0-0-02168" ref-type="bibr">10</xref>), with amplification and co-activation of both PDGFR-&#x03B1; and PDGFR-&#x03B2; being observed frequently in intimal sarcoma, whereas KIT levels were similar to those in normal tissue. Consistent with the above, PDGFR, EGFR and MDM2 have all been proposed as therapeutic targets in intimal sarcoma (<xref rid="b9-mco-0-0-02168" ref-type="bibr">9</xref>,<xref rid="b10-mco-0-0-02168" ref-type="bibr">10</xref>). Although early clinical trials have shown that the anti-PDGFR antibody olaratumab has antitumor activity in advanced soft-tissue sarcoma (<xref rid="b13-mco-0-0-02168" ref-type="bibr">13</xref>,<xref rid="b14-mco-0-0-02168" ref-type="bibr">14</xref>), a recent phase III study failed to demonstrate an additional effect of olaratumab when combined with doxorubicin in soft tissue sarcoma (<xref rid="b15-mco-0-0-02168" ref-type="bibr">15</xref>). However, PAIS was not included in the phase III study, and the role of PDGFR inhibitors in PAIS warrants further investigation. We did not observe expression of VEGFR-2 in our patients, and no previous reports have found raised levels of VEGFR in intimal sarcoma. We thus infer that VEGFR does not play an important role in PAIS pathogenesis.</p>
<p>Interpretation of our present study is limited, as the small case number precludes statistical analysis. Furthermore, in case 1, pazopanib was used as a first-line treatment, whereas in case 2, it was used as a third-line treatment; this does not allow a simple comparison of PFS in order to evaluate pazopanib efficacy. In addition, factors other than PDGFR and VEGFR expression are likely to determine the response to pazopanib. Allowing for these limitations, however, the strength of this study is that we evaluate the relationship between PDGFR expression and the therapeutic effect of pazopanib, in contrast to previous studies. In future studies, the relationship between the expression levels of PDGFR expression and the response to pazopanib needs to be verified with a larger sample population.</p>
<p>In conclusion, the present data suggest that PDGFR expression might be a potential predictor for the prediction of pazopanib efficacy.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgements</title>
<p>Not applicable.</p>
</ack>
<sec>
<title>Funding</title>
<p>Not applicable.</p>
</sec>
<sec>
<title>Availability of data and materials</title>
<p>All data generated or analyzed during this study are included in this published article.</p>
</sec>
<sec>
<title>Authors&#x0027; contributions</title>
<p>YI and SS made substantial contributions to the conception and design of the study. YH, KT and HS made substantial contributions to the acquisition of the data. SS drafted the manuscript. YI, NK, MT, YF, NC, YH, KT, HS, NJ and HM made substantial contributions to the analysis and interpretation of the data and were involved in revising the manuscript critically for important intellectual content. NJ performed the immunohistochemistry staining of intimal sarcoma of the pulmonary artery. All authors read and approved the final manuscript.</p>
</sec>
<sec>
<title>Ethics approval and consent to participate</title>
<p>Not applicable.</p>
</sec>
<sec>
<title>Patient consent for publication</title>
<p>Informed consent for publication of this case report was obtained from patients.</p>
</sec>
<sec>
<title>Competing interests</title>
<p>The authors declare that they have no competing interests.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="b1-mco-0-0-02168"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kr&#x00FC;ger</surname><given-names>I</given-names></name><name><surname>Borowski</surname><given-names>A</given-names></name><name><surname>Horst</surname><given-names>M</given-names></name><name><surname>de Vivie</surname><given-names>ER</given-names></name><name><surname>Theissen</surname><given-names>P</given-names></name><name><surname>Gross-Fengels</surname><given-names>W</given-names></name></person-group><article-title>Symptoms, diagnosis, and therapy of primary sarcomas of the pulmonary artery</article-title><source>Thorac Cardiovasc Surg</source><volume>38</volume><fpage>91</fpage><lpage>95</lpage><year>1990</year><pub-id pub-id-type="pmid">2190350</pub-id><pub-id pub-id-type="doi">10.1055/s-2007-1014001</pub-id></element-citation></ref>
<ref id="b2-mco-0-0-02168"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koll&#x00E1;r</surname><given-names>A</given-names></name><name><surname>Jones</surname><given-names>RL</given-names></name><name><surname>Stacchiotti</surname><given-names>S</given-names></name><name><surname>Gelderblom</surname><given-names>H</given-names></name><name><surname>Guida</surname><given-names>M</given-names></name><name><surname>Grignani</surname><given-names>G</given-names></name><name><surname>Steeghs</surname><given-names>N</given-names></name><name><surname>Safwat</surname><given-names>A</given-names></name><name><surname>Katz</surname><given-names>D</given-names></name><name><surname>Duffaud</surname><given-names>F</given-names></name><etal/></person-group><article-title>Pazopanib in advanced vascular sarcomas: An EORTC soft tissue and bone sarcoma group (STBSG) retrospective analysis</article-title><source>Acta Oncol</source><volume>56</volume><fpage>88</fpage><lpage>92</lpage><year>2017</year><pub-id pub-id-type="pmid">27838944</pub-id><pub-id pub-id-type="doi">10.1080/0284186X.2016.1234068</pub-id></element-citation></ref>
<ref id="b3-mco-0-0-02168"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schur</surname><given-names>S</given-names></name><name><surname>Hamacher</surname><given-names>R</given-names></name><name><surname>Brodowicz</surname><given-names>T</given-names></name></person-group><article-title>Pazopanib in primary cardiac angiosarcoma of the right atrium: A case report</article-title><source>Case Rep Oncol</source><volume>9</volume><fpage>363</fpage><lpage>367</lpage><year>2016</year><pub-id pub-id-type="pmid">27462238</pub-id><pub-id pub-id-type="doi">10.1159/000447088</pub-id></element-citation></ref>
<ref id="b4-mco-0-0-02168"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoo</surname><given-names>KH</given-names></name><name><surname>Kim</surname><given-names>HS</given-names></name><name><surname>Lee</surname><given-names>SJ</given-names></name><name><surname>Park</surname><given-names>SH</given-names></name><name><surname>Kim</surname><given-names>SJ</given-names></name><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>La Choi</surname><given-names>Y</given-names></name><name><surname>Shin</surname><given-names>KH</given-names></name><name><surname>Cho</surname><given-names>YJ</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Rha</surname><given-names>SY</given-names></name></person-group><article-title>Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: A retrospective case series</article-title><source>BMC Cancer</source><volume>15</volume><issue>154</issue><year>2015</year><pub-id pub-id-type="pmid">25885855</pub-id><pub-id pub-id-type="doi">10.1186/s12885-015-1160-x</pub-id></element-citation></ref>
<ref id="b5-mco-0-0-02168"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname><given-names>Y</given-names></name><name><surname>Toda</surname><given-names>K</given-names></name><name><surname>Miyagawa</surname><given-names>S</given-names></name><name><surname>Yoshikawa</surname><given-names>Y</given-names></name><name><surname>Hata</surname><given-names>H</given-names></name><name><surname>Domae</surname><given-names>K</given-names></name><name><surname>Matsuura</surname><given-names>R</given-names></name><name><surname>Sawa</surname><given-names>Y</given-names></name></person-group><article-title>Surgical resection and pazopanib treatment for recurrent cardiac angiosarcoma</article-title><source>Clin Pathol</source><volume>12</volume><issue>2632010X19831261</issue><year>2019</year><pub-id pub-id-type="pmid">31211293</pub-id><pub-id pub-id-type="doi">10.1177/2632010X19831261</pub-id></element-citation></ref>
<ref id="b6-mco-0-0-02168"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Graaf</surname><given-names>WT</given-names></name><name><surname>Blay</surname><given-names>JY</given-names></name><name><surname>Chawla</surname><given-names>SP</given-names></name><name><surname>Kim</surname><given-names>DW</given-names></name><name><surname>Bui-Nguyen</surname><given-names>B</given-names></name><name><surname>Casali</surname><given-names>PG</given-names></name><name><surname>Sch&#x00F6;ffski</surname><given-names>P</given-names></name><name><surname>Aglietta</surname><given-names>M</given-names></name><name><surname>Staddon</surname><given-names>AP</given-names></name><name><surname>Beppu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Pazopanib for metastatic soft-tissue sarcoma (PALETTE): A randomised, double-blind, placebo-controlled phase 3 trial</article-title><source>Lancet</source><volume>379</volume><fpage>1879</fpage><lpage>1886</lpage><year>2012</year><pub-id pub-id-type="pmid">22595799</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(12)60651-5</pub-id></element-citation></ref>
<ref id="b7-mco-0-0-02168"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dewaele</surname><given-names>B</given-names></name><name><surname>Floris</surname><given-names>G</given-names></name><name><surname>Finalet-Ferreiro</surname><given-names>J</given-names></name><name><surname>Fletcher</surname><given-names>CD</given-names></name><name><surname>Coindre</surname><given-names>JM</given-names></name><name><surname>Guillou</surname><given-names>L</given-names></name><name><surname>Hogendoorn</surname><given-names>PC</given-names></name><name><surname>Wozniak</surname><given-names>A</given-names></name><name><surname>Vanspauwen</surname><given-names>V</given-names></name><name><surname>Sch&#x00F6;ffski</surname><given-names>P</given-names></name><etal/></person-group><article-title>Coactivated platelet-derived growth factor receptor &#x007B;alpha&#x007D; and epidermal growth factor receptor are potential therapeutic targets in intimal sarcoma</article-title><source>Cancer Res</source><volume>70</volume><fpage>7304</fpage><lpage>7314</lpage><year>2010</year><pub-id pub-id-type="pmid">20685895</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-1543</pub-id></element-citation></ref>
<ref id="b8-mco-0-0-02168"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sirvent</surname><given-names>N</given-names></name><name><surname>Maire</surname><given-names>G</given-names></name><name><surname>Pedeutour</surname><given-names>F</given-names></name></person-group><article-title>Genetics of dermatofibrosarcoma protuberans family of tumors: From ring chromosomes to tyrosine kinase inhibitor treatment</article-title><source>Genes Chromosomes Cancer</source><volume>37</volume><fpage>1</fpage><lpage>19</lpage><year>2003</year><pub-id pub-id-type="pmid">12661001</pub-id><pub-id pub-id-type="doi">10.1002/gcc.10202</pub-id></element-citation></ref>
<ref id="b9-mco-0-0-02168"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ito</surname><given-names>Y</given-names></name><name><surname>Maeda</surname><given-names>D</given-names></name><name><surname>Yoshida</surname><given-names>M</given-names></name><name><surname>Yoshida</surname><given-names>A</given-names></name><name><surname>Kudo-Asabe</surname><given-names>Y</given-names></name><name><surname>Nanjyo</surname><given-names>H</given-names></name><name><surname>Izumi</surname><given-names>C</given-names></name><name><surname>Yamamoto</surname><given-names>F</given-names></name><name><surname>Inoue</surname><given-names>M</given-names></name><name><surname>Shibata</surname><given-names>H</given-names></name><etal/></person-group><article-title>Cardiac intimal sarcoma with PDGFR&#x03B2; mutation and co-amplification of PDGFR&#x03B1; and MDM2: An autopsy case analyzed by whole-exome sequencing</article-title><source>Virchows Arch</source><volume>471</volume><fpage>423</fpage><lpage>428</lpage><year>2017</year><pub-id pub-id-type="pmid">28474091</pub-id><pub-id pub-id-type="doi">10.1007/s00428-017-2135-x</pub-id></element-citation></ref>
<ref id="b10-mco-0-0-02168"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tamborini</surname><given-names>E</given-names></name><name><surname>Casieri</surname><given-names>P</given-names></name><name><surname>Miselli</surname><given-names>F</given-names></name><name><surname>Orsenigo</surname><given-names>M</given-names></name><name><surname>Negri</surname><given-names>T</given-names></name><name><surname>Piacenza</surname><given-names>C</given-names></name><name><surname>Stacchiotti</surname><given-names>S</given-names></name><name><surname>Gronchi</surname><given-names>A</given-names></name><name><surname>Pastorino</surname><given-names>U</given-names></name><name><surname>Pierotti</surname><given-names>MA</given-names></name><name><surname>Pilotti</surname><given-names>S</given-names></name></person-group><article-title>Analysis of potential receptor tyrosine kinase targets in intimal and mural sarcomas</article-title><source>J Pathol</source><volume>212</volume><fpage>227</fpage><lpage>235</lpage><year>2007</year><pub-id pub-id-type="pmid">17471466</pub-id><pub-id pub-id-type="doi">10.1002/path.2177</pub-id></element-citation></ref>
<ref id="b11-mco-0-0-02168"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bode-Lesniewska</surname><given-names>B</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Speel</surname><given-names>EJ</given-names></name><name><surname>Biraima</surname><given-names>AM</given-names></name><name><surname>Turina</surname><given-names>M</given-names></name><name><surname>Komminoth</surname><given-names>P</given-names></name><name><surname>Heitz</surname><given-names>PU</given-names></name></person-group><article-title>Gains of 12q13-14 and overexpression of mdm2 are frequent findings in intimal sarcomas of the pulmonary artery</article-title><source>Virchows Arch</source><volume>438</volume><fpage>57</fpage><lpage>65</lpage><year>2001</year><pub-id pub-id-type="pmid">11213836</pub-id><pub-id pub-id-type="doi">10.1007/s004280000313</pub-id></element-citation></ref>
<ref id="b12-mco-0-0-02168"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tajima</surname><given-names>S</given-names></name><name><surname>Takanashi</surname><given-names>Y</given-names></name><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Neyatani</surname><given-names>H</given-names></name></person-group><article-title>Intimal sarcoma of the abdominal aorta with platelet-derived growth factor receptor &#x03B1; overexpression and amplification in mural invasive cells and pulmonary metastatic cells but not in intimal spreading cells</article-title><source>Pathol Int</source><volume>65</volume><fpage>426</fpage><lpage>431</lpage><year>2015</year><pub-id pub-id-type="pmid">25998154</pub-id><pub-id pub-id-type="doi">10.1111/pin.12308</pub-id></element-citation></ref>
<ref id="b13-mco-0-0-02168"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tap</surname><given-names>WD</given-names></name><name><surname>Jones</surname><given-names>RL</given-names></name><name><surname>Van Tine</surname><given-names>BA</given-names></name><name><surname>Chmielowski</surname><given-names>B</given-names></name><name><surname>Elias</surname><given-names>AD</given-names></name><name><surname>Adkins</surname><given-names>D</given-names></name><name><surname>Agulnik</surname><given-names>M</given-names></name><name><surname>Cooney</surname><given-names>MM</given-names></name><name><surname>Livingston</surname><given-names>MB</given-names></name><name><surname>Pennock</surname><given-names>G</given-names></name><etal/></person-group><article-title>Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: An open-label phase 1b and randomised phase 2 trial</article-title><source>Lancet</source><volume>388</volume><fpage>488</fpage><lpage>497</lpage><year>2016</year><pub-id pub-id-type="pmid">27291997</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(16)30587-6</pub-id></element-citation></ref>
<ref id="b14-mco-0-0-02168"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yonemori</surname><given-names>K</given-names></name><name><surname>Kodaira</surname><given-names>M</given-names></name><name><surname>Satoh</surname><given-names>T</given-names></name><name><surname>Kudo</surname><given-names>T</given-names></name><name><surname>Takahashi</surname><given-names>S</given-names></name><name><surname>Nakano</surname><given-names>K</given-names></name><name><surname>Ando</surname><given-names>Y</given-names></name><name><surname>Shimokata</surname><given-names>T</given-names></name><name><surname>Mori</surname><given-names>J</given-names></name><name><surname>Inoue</surname><given-names>K</given-names></name><etal/></person-group><article-title>Phase 1 study of olaratumab plus doxorubicin in Japanese patients with advanced soft-tissue sarcoma</article-title><source>Cancer Sci</source><volume>109</volume><fpage>3962</fpage><lpage>3970</lpage><year>2018</year><pub-id pub-id-type="pmid">30353601</pub-id><pub-id pub-id-type="doi">10.1111/cas.13846</pub-id></element-citation></ref>
<ref id="b15-mco-0-0-02168"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tap</surname><given-names>WD</given-names></name><name><surname>Wagner</surname><given-names>AJ</given-names></name><name><surname>Sch&#x00F6;ffski</surname><given-names>P</given-names></name><name><surname>Martin-Broto</surname><given-names>J</given-names></name><name><surname>Krarup-Hansen</surname><given-names>A</given-names></name><name><surname>Ganjoo</surname><given-names>KN</given-names></name><name><surname>Yen</surname><given-names>CC</given-names></name><name><surname>Abdul Razak</surname><given-names>AR</given-names></name><name><surname>Spira</surname><given-names>A</given-names></name><name><surname>Kawai</surname><given-names>A</given-names></name><etal/></person-group><article-title>Effect of doxorubicin plus olaratumab vs. doxorubicin plus placebo on survival in patients with advanced soft tissue sarcomas: The ANNOUNCE randomized clinical trial</article-title><source>JAMA</source><volume>323</volume><fpage>1266</fpage><lpage>1276</lpage><year>2020</year><pub-id pub-id-type="pmid">32259228</pub-id><pub-id pub-id-type="doi">10.1001/jama.2020.1707</pub-id></element-citation></ref>
</ref-list>
</back>
<floats-group>
<fig id="f1-mco-0-0-02168" position="float">
<label>Figure 1</label>
<caption><p>Immunohistochemistry staining (magnification, x200). (A) PDGFR-&#x03B1; (Cell Signaling Technology, Inc.; cat. no. 3174), (B) PDGFR-&#x03B2; (Abcam; cat. no. 32570), (C) VEGFR-2 (Cell Signaling Technology, Inc.; cat. no. 2479). PDGFR, platelet-derived growth factor receptor; VEGFR, vascular endothelial growth factor receptor.</p></caption>
<graphic xlink:href="mco-14-01-02168-g00.tif" />
</fig>
<table-wrap id="tI-mco-0-0-02168" position="float">
<label>Table I</label>
<caption><p>Main characteristics and patient outcomes.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="middle" colspan="7">&#x00A0;</th>
<th align="center" valign="middle" colspan="4">Sequential therapy</th>
<th align="center" valign="middle" colspan="3">Immunohistochemical staining</th>
<th align="center" valign="middle">&#x00A0;</th>
</tr>
<tr>
<th align="left" valign="middle">Case</th>
<th align="center" valign="middle">Age</th>
<th align="center" valign="middle">Sex</th>
<th align="center" valign="middle">Metastatic lesion</th>
<th align="center" valign="middle">Resection</th>
<th align="center" valign="middle">Adjuvant therapy</th>
<th align="center" valign="middle">RFS (months)</th>
<th align="center" valign="middle">Regimen</th>
<th align="center" valign="middle">Best response</th>
<th align="center" valign="middle">PFS (months)</th>
<th align="center" valign="middle">OS (months)</th>
<th align="center" valign="middle">PDGFR-&#x03B1;</th>
<th align="center" valign="middle">PDGFR-&#x03B2;</th>
<th align="center" valign="middle">VEGFR-2</th>
<th align="center" valign="middle">PFS (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="middle">1</td>
<td align="center" valign="middle">33</td>
<td align="left" valign="middle">Male</td>
<td align="center" valign="middle">Lung</td>
<td align="center" valign="middle">R1</td>
<td align="center" valign="middle">RT + AI</td>
<td align="center" valign="middle">7.5</td>
<td align="left" valign="middle">1st: Pazopanib</td>
<td align="center" valign="middle">SD</td>
<td align="center" valign="middle">5.8</td>
<td align="center" valign="middle">18.0</td>
<td align="left" valign="middle">Moderate</td>
<td align="left" valign="middle">Strong</td>
<td align="left" valign="middle">Negative</td>
<td align="center" valign="middle">5.8</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">2nd: Eribulin</td>
<td align="center" valign="middle">PD</td>
<td align="center" valign="middle">0.4</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">Positive</td>
<td align="left" valign="middle">Positive</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">2</td>
<td align="center" valign="middle">44</td>
<td align="left" valign="middle">Female</td>
<td align="center" valign="middle">Lung</td>
<td align="center" valign="middle">R2</td>
<td align="center" valign="middle">-</td>
<td align="center" valign="middle">3.1</td>
<td align="left" valign="middle">1st: Doxorubicin</td>
<td align="center" valign="middle">SD</td>
<td align="center" valign="middle">4.7</td>
<td align="center" valign="middle">14.3</td>
<td align="left" valign="middle">Weak</td>
<td align="left" valign="middle">Weak</td>
<td align="left" valign="middle">Negative</td>
<td align="center" valign="middle">1.1</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">2nd: Eribulin</td>
<td align="center" valign="middle">SD</td>
<td align="center" valign="middle">1.0</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">Positive</td>
<td align="left" valign="middle">Positive</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">3rd: Pazopanib</td>
<td align="center" valign="middle">SD</td>
<td align="center" valign="middle">1.1</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn><p>RFS, recurrence-free survival; PFS, progression-free survival; OS, overall survival; RT, radiation therapy; AI, adriamycin + ifosfamide; SD, stable disease; PD, progression disease; PDGFR, platelet-derived growth factor receptor; VEGFR, vascular endothelial growth factor receptor.</p></fn>
</table-wrap-foot>
</table-wrap>
</floats-group>
</article>
